GlassScriptPhysician profile
Andrew Wargo
NPI 1306609458
$6,367.11
in general payments reported to CMS, 2019-2025
22 companies · $3,680 in 2025
The $3,680 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $78.65 · 2024: $2,608 · 2025: $3,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,251 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,251.09 |
| Education | $116.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $767.24 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $744.93 | 2024-2025 | Auvelity, Sunosi |
| Abbvie INC. | $693.22 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $670.24 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $580.06 | 2024-2025 | Rexulti, Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $440.76 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $381.04 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $357.53 | 2024-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $297.92 | 2024-2025 | Trintellix |
| Corium, LLC | $248.19 | 2024-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $205.37 | 2024-2025 | Spravato |
| Bausch Health US, LLC | $173.29 | 2024-2025 | Aplenzin, Wellbutrin |
| Collegium Pharmaceutical, INC. | $162.73 | 2025 | Jornay Pm |
| Alkermes, INC. | $145.74 | 2024-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $137.80 | 2024 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $95.65 | 2024-2025 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $76.49 | 2024-2025 | Quviviq, Quviviq |
| Ironshore Pharmaceuticals INC. | $70.07 | 2024 | |
| Tms Neurohealth Centers INC. | $47.18 | 2025 | Tms Neurohealth Centers INC. |
| Harmony Biosciences LLC | $31.94 | 2024 | |
| Validus Pharmaceuticals LLC | $21.33 | 2024 | Equetro |
| Almatica Pharma LLC | $18.39 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Wargo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.